

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)



(10) International Publication Number
WO 2020/168271 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 1/04* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2020/018405

(22) International Filing Date:
14 February 2020 (14.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/806,604 15 February 2019 (15.02.2019) US
62/925,704 24 October 2019 (24.10.2019) US

(71) Applicant: ALLAKOS INC. [US/US]; 975 Island Drive,
#201, Redwood City, California 94065 (US).

(72) Inventors: **YOUNGBLOOD, Bradford Andrew**; c/o Allakos Inc., 975 Island Drive, #201, Redwood City, California 94065 (US). **SINGH, Bhupinder**; c/o Allakos Inc., 975 Island Drive, #201, Redwood City, California 94065 (US). **KAMBOJ, Amol**; c/o Allakos Inc., 975 Island Drive, #201, Redwood City, California 94065 (US). **GREENWOOD, Simon**; c/o Allakos Inc., 975 Island Drive, #201, Redwood City, California 94065 (US). **RASMUSSEN, Henrik**; c/o Allakos Inc., 975 Island Drive, #201, Redwood City, California 94065 (US).

(74) Agent: **JONES, Kevin Theodore** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING MAST CELL GASTRITIS, MAST CELL ESOPHAGITIS, MAST CELL ENTERITIS, MAST CELL DUODENITIS, AND/OR MAST CELL GASTROENTERITIS




FIG. 7

(57) Abstract: The present disclosure provides methods for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis. In particular, the present disclosure provides methods for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of mast cell gastritis, mast cell esophagitis, mast cell colitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis.

[Continued on next page]

WO 2020/168271 A1

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))